Univercells Technologies, a leader in bioprocessing innovations, introduces the scale-X™ nexo bioreactor—a fixed-bed, miniaturized bioreactor with a 0.5 m² growth surface, tailored to meet the needs of contract labs engaged in cell culture process development. The scale-X nexo offers direct scalability to larger bioreactors, enabling labs to transition from development to commercial production efficiently, making it ideal for cell and gene therapies, vaccines, and other biopharma applications.
Key Benefits of scale-X nexo for Contract Labs
- Lower Resource Use: Cuts media and reagent consumption, saving costs and resources per run.
- Scalability from Lab to Commercial Production: Direct path to larger scale-X bioreactors for seamless scaling.
- Reduced Development Timelines: Streamlined setup and quick optimization of process conditions.
- Skaia™ Integration for Non-Invasive Monitoring: Allows cell count estimation without direct sampling.
For contract labs, the scale-X nexo bioreactor delivers cost efficiency, scalability, and time-saving capabilities, enabling high-performance bioprocessing with optimized resource usage.
This article is an AI generated summary of a published press release provided by Univercells Technologies
